- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,507 of 2,219.
| EudraCT Number: 2014-000657-36 | Sponsor Protocol Number: 46934 | Start Date*: 2015-06-22 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions | ||
| Medical condition: Parkinson's disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-001146-38 | Sponsor Protocol Number: B7471016 | Start Date*: 2022-09-27 |
| Sponsor Name:Pfizer Inc. | ||
| Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS | ||
| Medical condition: Pneumococcal disease | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004731-12 | Sponsor Protocol Number: uni-koeln-1782 | Start Date*: 2016-07-20 |
| Sponsor Name:University of Cologne | ||
| Full Title: Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment | ||
| Medical condition: Primary rhegmatogenous retinal detachment (RRD) accompanied by elevated protein levels in anterior chamber fluid (laser flare value ≥15pc/ms). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002470-42 | Sponsor Protocol Number: FluSHED-2 | Start Date*: 2018-08-30 | |||||||||||
| Sponsor Name:Imperial College London JRC Office | |||||||||||||
| Full Title: Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study | |||||||||||||
| Medical condition: Prevention of influenza infection through immunisation | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000686-16 | Sponsor Protocol Number: CHDR1953 | Start Date*: 2020-03-26 | |||||||||||
| Sponsor Name:Centre for Human Drug Research | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients. | |||||||||||||
| Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002368-15 | Sponsor Protocol Number: PS0016 | Start Date*: 2016-11-15 | |||||||||||
| Sponsor Name:UCB Biopharma SPRL | |||||||||||||
| Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderat... | |||||||||||||
| Medical condition: Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005370-62 | Sponsor Protocol Number: ANAKIN-RA-DIABETES | Start Date*: 2013-02-18 | ||||||||||||||||
| Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA | ||||||||||||||||||
| Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe... | ||||||||||||||||||
| Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-005529-25 | Sponsor Protocol Number: API-EAG-2021-01 | Start Date*: 2022-10-14 | |||||||||||
| Sponsor Name:ASAC Pharmaceutical Inmunology, S.A. | |||||||||||||
| Full Title: In vivo Biological Standardization of Gramineae Allergenic Extracts | |||||||||||||
| Medical condition: Biological standarization for allergenic extracts in patients with hipersensibility to extract | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-000253-92 | Sponsor Protocol Number: EHP-101-MS02 | Start Date*: 2022-10-14 | |||||||||||||||||||||
| Sponsor Name:Emerald Health Pharmaceuticals Inc. | |||||||||||||||||||||||
| Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 | |||||||||||||||||||||||
| Medical condition: Relapsing Forms of Multiple Sclerosis (RMS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2005-004207-11 | Sponsor Protocol Number: Gd-NEPHRIC-01 | Start Date*: 2006-01-03 |
| Sponsor Name:Malmö University Hospital, Dep of Radiology | ||
| Full Title: Single blind study comparing nephrotoxicity in patients with decreased renal function after intravenous gadodiamide(Omniscan) or gadopenteate (Magnevist) injection in routine clinical Magnetic Reso... | ||
| Medical condition: Patients with diabetes (type I or II) and impaired renal function defined as pre-study serum creatinine ≥150µmol/l if man and 133µmol/l if woman or an estimated prestudy glomerular filtration rate ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000666-20 | Sponsor Protocol Number: COPD1 | Start Date*: 2007-06-14 | |||||||||||
| Sponsor Name:Royal Bournemouth Hospital | |||||||||||||
| Full Title: Influence of insulin therapy in non-diabetic patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease (COPD) | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001373-70 | Sponsor Protocol Number: ET20-076 | Start Date*: 2020-04-01 |
| Sponsor Name:Centre Léon Bérard | ||
| Full Title: IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizu... | ||
| Medical condition: Patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002181-20 | Sponsor Protocol Number: NTX2010-2-0130 | Start Date*: 2011-12-29 | |||||||||||
| Sponsor Name:Oslo University Hospital [...] | |||||||||||||
| Full Title: Naltrexone Implants for Alcoholism | |||||||||||||
| Medical condition: Alcohol dependence in outpatients. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002669-40 | Sponsor Protocol Number: ALD518-CLIN-009 | Start Date*: 2011-12-15 | |||||||||||
| Sponsor Name:Alder BioPharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Ne... | |||||||||||||
| Medical condition: Oral Mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000330-61 | Sponsor Protocol Number: CHI-DIP-2016-01 | Start Date*: 2017-05-16 | |||||||||||
| Sponsor Name:CHIESI ESPAÑA S.A.U. | |||||||||||||
| Full Title: Effect of Beclometasone dipropionate (BDP) on faecal Calprotectin levels in patients with clinically inactive Ulcerative Colitis at risk of relapse. BeCalCU study | |||||||||||||
| Medical condition: Clinically inactive Ulcerative Colitis at risk of relapse | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000679-28 | Sponsor Protocol Number: FAZA-gliomi | Start Date*: 2015-07-13 | |||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
| Full Title: Prognostic value of 18F-FAZA PET/CT in high grade glioma: comparison with MRI and correlation with hypoxia biomarkers. | |||||||||||||
| Medical condition: Patients with high-grade glioma (III-IV). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005595-35 | Sponsor Protocol Number: CHDR2036 | Start Date*: 2021-02-11 | |||||||||||
| Sponsor Name:Centre for Human Drug Research | |||||||||||||
| Full Title: A dermal inflammatory challenge study to evaluate complement activation in healthy volunteers | |||||||||||||
| Medical condition: Inflammation / Complement activation | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014643-36 | Sponsor Protocol Number: MeBe/08/NEB-MICR/001 | Start Date*: 2010-04-23 |
| Sponsor Name:MENARINI Benelux NV/SA | ||
| Full Title: Effects Of The Administration Of Nebivolol Versus Carvedilol On Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection In Healthy Volunteers” (NeCaMic-study) | ||
| Medical condition: Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: BE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003656-40 | Sponsor Protocol Number: PCYC-1128-CA | Start Date*: 2016-02-17 | ||||||||||||||||||||||||||
| Sponsor Name:Pharmacyclics LLC | ||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors | ||||||||||||||||||||||||||||
| Medical condition: Metastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2016-001760-10 | Sponsor Protocol Number: AGMT_NHL-15B | Start Date*: 2016-10-24 | ||||||||||||||||
| Sponsor Name:AGMT gGmbH | ||||||||||||||||||
| Full Title: Phase II single-arm “window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | ||||||||||||||||||
| Medical condition: Early relapsed or refractory diffuse large B-cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.